AstraZeneca’s (AZN) Sell Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their sell rating on shares of AstraZeneca (LON:AZN) in a report published on Wednesday morning,Digital Look reports. They currently have a £115 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on AZN. Citigroup upped their target price on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Berenberg Bank restated a “buy” rating and set a £160 price target on shares of AstraZeneca in a research report on Tuesday, July 28th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Monday, August 3rd. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £152.17.

AstraZeneca Price Performance

Shares of LON:AZN opened at £120.06 on Wednesday. The company’s fifty day moving average price is £125.70 and its 200-day moving average price is £136.70. The firm has a market capitalization of £186.20 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 0.86 and a beta of 0.21. AstraZeneca has a one year low of £107.84 and a one year high of £157.32. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.